Danaher Corporation $DHR Shares Sold by Banque Transatlantique SA

Key Points

• Banque Transatlantique SA reduced its stake in Danaher Corporation by 41.8% in the first quarter, selling 107,762 shares, leaving them with 149,833 shares valued at approximately $28.4 million.
• Danaher has received multiple ratings updates, with Robert W. Baird increasing the target price to $226 and Guggenheim maintaining a buy rating with a target price of $250.
• The company reported $1.80 EPS for the last quarter, surpassing analysts’ expectations, and has set FY 2025 guidance at 7.700-7.800 EPS.

Banque Transatlantique SA lowered its stake in Danaher Corporation (NYSE:DHR - Free Report) by 41.8% during the first quarter, according to its most recent Form 13F filing with the SEC. The firm owned 149,833 shares of the conglomerate's stock after selling 107,762 shares during the period. Banque Transatlantique SA's holdings in Danaher were worth $28,385,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. GHP Investment Advisors Inc. grew its holdings in shares of Danaher by 396.0% during the first quarter. GHP Investment Advisors Inc. now owns 124 shares of the conglomerate's stock worth $25,000 after purchasing an additional 99 shares during the last quarter. Heck Capital Advisors LLC bought a new position in shares of Danaher in the 4th quarter worth $27,000. Sierra Ocean LLC lifted its stake in Danaher by 116.9% during the 1st quarter. Sierra Ocean LLC now owns 141 shares of the conglomerate's stock valued at $29,000 after acquiring an additional 76 shares in the last quarter. Smallwood Wealth Investment Management LLC bought a new position in Danaher during the 1st quarter valued at $31,000. Finally, Dunhill Financial LLC lifted its stake in Danaher by 68.4% during the 1st quarter. Dunhill Financial LLC now owns 165 shares of the conglomerate's stock valued at $34,000 after acquiring an additional 67 shares in the last quarter. Institutional investors own 79.05% of the company's stock.

Danaher Price Performance

Shares of NYSE:DHR traded up $1.29 during trading on Friday, hitting $200.32. 2,837,584 shares of the company's stock were exchanged, compared to its average volume of 2,859,442. The business's 50-day simple moving average is $201.93 and its 200 day simple moving average is $199.37. Danaher Corporation has a 52-week low of $171.00 and a 52-week high of $279.90. The company has a market cap of $143.44 billion, a price-to-earnings ratio of 42.62, a PEG ratio of 2.79 and a beta of 0.75. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.62 and a quick ratio of 1.22.

Danaher (NYSE:DHR - Get Free Report) last posted its quarterly earnings data on Tuesday, July 22nd. The conglomerate reported $1.80 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.64 by $0.16. Danaher had a return on equity of 10.70% and a net margin of 14.21%.The business had revenue of $5.94 billion during the quarter, compared to analyst estimates of $5.83 billion. During the same period last year, the company earned $1.72 EPS. The company's revenue for the quarter was up 3.4% on a year-over-year basis. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. As a group, equities analysts predict that Danaher Corporation will post 7.63 EPS for the current year.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on DHR. Deutsche Bank Aktiengesellschaft decreased their price objective on Danaher from $240.00 to $235.00 in a report on Thursday, June 5th. Wells Fargo & Company dropped their price target on Danaher from $210.00 to $205.00 and set an "equal weight" rating for the company in a research report on Wednesday, July 23rd. UBS Group dropped their target price on Danaher from $240.00 to $225.00 and set a "buy" rating for the company in a research report on Wednesday, July 23rd. Evercore ISI decreased their price target on Danaher from $230.00 to $226.00 and set an "outperform" rating on the stock in a research note on Tuesday, July 8th. Finally, Barclays reissued an "overweight" rating and set a $225.00 target price (up from $215.00) on shares of Danaher in a research note on Tuesday, June 24th. Seventeen analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $246.35.

Insiders Place Their Bets

In other Danaher news, Director Teri List sold 2,778 shares of Danaher stock in a transaction dated Friday, August 22nd. The stock was sold at an average price of $211.06, for a total transaction of $586,324.68. Following the completion of the sale, the director owned 20,751 shares of the company's stock, valued at approximately $4,379,706.06. The trade was a 11.81% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. 11.10% of the stock is currently owned by company insiders.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.